Abstract:10008 Background: The identification of markers predictive of neoadjuvant chemotherapy response would be an important advance. Therefore, we sought to identify gene expression profiles predictive of neoadjuvant response and evaluated their drug specificity. Methods: DNA microarray analysis was performed on pre-treatment core biopsies from two different locally advanced breast cancer patient sets receiving neoadjuvant chemotherapy; the first set (L9819) was treated with 4 cycles of doxorubicin + cyclophosphamide (AC) followed by 4 cycles of paclitaxel (T) or paclitaxel + trastuzumab (TH). The second patient set (S329) received 4 cycles of gemcitabine + doxorubicin followed by 4 cycles of gemcitabine + cisplatin. Clinical response was based on RECIST criteria. Results: We obtained successful microarrays on 44 (L9819) and 46 (S329) of the patients enrolled. Ten-fold cross-validated supervised analyses separately performed on each dataset identified gene expression patterns that accurately predicted (75–85% accuracy) response (clinical complete responders vs. others) evaluated on those patients that completed all 8 cycles of chemotherapy. The predictive expression patterns from the L9819 trial were significantly enriched for apoptosis genes, while the predictive gene set from the S329 trial was enriched for nucleotide metabolism genes. The L9819 predictor was able to accurately predict (75% accuracy) response for the S329 patients, however, the S329 predictor was not able to predict response on the L9819 trial (50% accuracy). We speculate that the L9819 predictor was able to predict response on the S329 dataset (despite the fact that only doxorubicin was common to both trials) because this profile was enriched for apoptosis genes that may reflect a general mechanism of chemotherapy response/resistance, while the S329 predictor was more tuned to gemcitabine’s specific mechanism of action. Conclusions: This study may provide the means to predict response to AC-T(H) and GA-GC neoadjuvant chemotherapy. The ability of one predictor to work on the other dataset, but not vise versa, suggests that both general chemotherapy and drug specific response profiles may have been identified. [Table: see text]

Gene Expression Patterns Within Cell Lines Are Predictive of Chemosensitivity

Prediction of Drug Efficacy for Cancer Treatment Based on Comparative Analysis of Chemosensitivity and Gene Expression Data

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Correlating chemical sensitivity and basal gene expression reveals mechanism of action

Systematic variation in gene expression patterns in human cancer cell lines

Systematic identification of genomic markers of drug sensitivity in cancer cells

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

Genetic and Expression Profiles of Squamous Cell Carcinoma of the Head and Neck Correlate with Cisplatin Sensitivity and Resistance in Cell Lines and Patients

A gene expression database for the molecular pharmacology of cancer

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Characterization of Expression-Based Gene Clusters Gives Insights into Variation in Patient Response to Cancer Therapies

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response

Prediction of Chemosensitivity in Multiple Primary Cancer Patients Using Machine Learning

Large-Scale Transcriptional Profiling of Molecular Perturbations Reveals Cell Line Specific Responses and Implications for Environmental Screening

Comparative Analysis And Integrative Classification Of Nc160 Cell Lines And Primary Tumors Using Gene Expression Profiling Data

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity

Cell morphology and gene expression: tracking changes and complementarity across time and cell lines

Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data

Expression Profiles Can Predict Both General Chemotherapy and Gemcitabine-Specific Responses in Breast Cancer Patients Receiving Neoadjuvant Therapy

Learning and actioning general principles of cancer cell drug sensitivity